ASCO 2022 Conference Coverage

 

ASCO 2022 Conference Coverage
J

ASCO 2022 on Long-Term Toxicities With Immune Checkpoint Inhibitor in Melanoma Patients

By ASCO 2022 Conference Coverage FEATURING Justin Tong
By ASCO 2022 Conference Coverage FEATURING Justin Tong
0 views
June 21, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse

Featured Video

05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy
Skin
10:27
ASCO 2022 Conference Coverage

ASCO 2022 Updates on DREAMseq (Doublet, Randomized Evaluation in Adv…

Feat. M. Atkins
01:37
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Anti-PD-1 Antibody: Plus One or Plus …

Feat. A. Daud
18:11
ASCO 2022 Conference Coverage

ASCO 2022 on Anti-PD-1 Antibody: Plus One or Plus Two

Feat. A. Daud
14:22
ASCO 2022 Conference Coverage

ASCO 2022 Nivo + Rela vs. Nivo in Previously Untreated Metastatic/Un…

Feat. E. Lipson
02:01
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Meta-Analysis of Randomized Phase II-III…

Feat. P. Francesco Ferrucci
09:28
ASCO 2022 Conference Coverage

ASCO 2022 Meta-Analysis of Randomized Phase II-III Trials Evaluating…

Feat. P. Francesco Ferrucci
05:48
ASCO 2022 Conference Coverage

ASCO 2022 on the Role of Metastasectomy in Advanced BRAF+ Melanoma D…

Feat. K. Orlova
04:30
ASCO 2022 Conference Coverage

ASCO 2022 on ARTISTRY-6 Trial: Nemvaleukin Alfa Monotherapy in Advan…

Feat. J. Weber
50
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on ARTISTRY-6 Trial: Nemvaleukin Alfa Mo…

Feat. J. Weber
27
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Long-Term Toxicities With Immune Chec…

Feat. J. Tong
11:46
ASCO 2022 Conference Coverage

ASCO 2022 on Long-Term Toxicities With Immune Checkpoint Inhibitor i…

Feat. J. Tong
05:28
ASCO 2022 Conference Coverage

ASCO 2022 Primary Ipi/Nivo Followed by Adjuvant Nivo in Pts With Loc…

Feat. E. Cocorocchio
06:03
ASCO 2022 Conference Coverage

ASCO 2022 on Survival Update of Neoadjuvant Ipi + Nivo in Macroscopi…

Feat. J. Versluis
07:54
ASCO 2022 Conference Coverage

ASCO 2022 Phase II SECOMBIT Study on Optimal Treatment Sequencing in…

Feat. P. Ascierto
01:23
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Thromboembolism and Association With …

Feat. T. Sussman
08:48
ASCO 2022 Conference Coverage

ASCO 2022 on Thromboembolism and Association With Survival in Pts Wi…

Feat. T. Sussman
16:53
ASCO 2022 Conference Coverage

ASCO 2022: Real-World Evaluation of the Association Between Baseline…

Feat. Z. Eroglu
09:33
ASCO 2022 Conference Coverage

ASCO 2022 on ImmunoCobiVem Study Interim Analysis: The Efficacy &…

Feat. E. Livingstone
55
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Nivolumab + Relatlimab vs. Nivo in 1L Me…

Feat. P. Rutkowski
05:06
ASCO 2022 Conference Coverage

ASCO 2022 on RELATIVITY-047 Trial: Nivolumab + Relatlimab vs. Nivo i…

Feat. P. Rutkowski
45
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Long-Term Survival in Advanced Melanoma …

Feat. P. Rutkowski
04:49
ASCO 2022 Conference Coverage

ASCO 2022 Long-Term Survival in Advanced Melanoma for Pts Treated Wi…

Feat. P. Rutkowski
14:06
ASCO 2022 Conference Coverage

ASCO 2022 Analysis of the Effect of Systemic Corticosteroids on Surv…

Feat. A. Ikeguchi